Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy.

about

Statins and their increased risk of inducing diabetes.Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia.Lunasin functionally enhances LDL uptake via inhibiting PCSK9 and enhancing LDLR expression in vitro and in vivo.

P2860

Q38599323-4E712E00-A741-44FF-8ECD-11A4B82F03CD Q38644072-2501C99E-15D8-415B-838C-447119B1D0A7 Q47132548-F3DA13B6-A048-4129-97E9-C04626585056

P2860

Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy.

Item

http://www.wikidata.org/entity/Q38285812

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Proprotein convertase subtilis ...... ion in lipid-lowering therapy.

@en

type

Item

label

Proprotein convertase subtilis ...... ion in lipid-lowering therapy.

@en

prefLabel

Proprotein convertase subtilis ...... ion in lipid-lowering therapy.

@en

P1476

Proprotein convertase subtilis ...... ion in lipid-lowering therapy.

@en

P2093

George Liamis

http://www.w3.org/2001/XMLSchema#string

Haralampos Milionis

http://www.w3.org/2001/XMLSchema#string

P2860

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions

Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data.

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

P304

287-298

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2015.984682

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Moses Elisaf

P577

2014-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25491324

http://www.w3.org/2001/XMLSchema#string

Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy.

about

P2860

P2860

Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698